Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 11/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408135 | 0.88 | KCNMA1 (0.55) | HSPA5KCNMA1POLBCHRNA7MEN1 | |
| SCHEMBL6410312 | 0.83 | KCNMA1 (0.52) | HSPA5KCNMA1POLBCHRNA7STAT3 | |
| SCHEMBL6410292 | 0.83 | HSPA5 (0.62) | HSPA5POLBCA1CA2MEN1 | |
| SCHEMBL6412941 | 0.82 | CA1 (0.57) | CA1CA2MAPT | |
| SCHEMBL6414640 | 0.82 | ACLY (0.49) | HSPA5KCNMA1POLBCA1CA2 | |
| SCHEMBL6407663 | 0.81 | NPC1 (0.50) | HSPA5KCNMA1POLBMEN1MAPT | |
| SCHEMBL6415355 | 0.80 | HSPA5 (0.44) | HSPA5KCNMA1POLBMEN1MAPT | |
| SCHEMBL6408459 | 0.80 | ACLY (0.59) | KCNMA1HDAC1 | |
| SCHEMBL6416161 | 0.80 | MEN1 (0.52) | HSPA5KCNMA1POLBMEN1MAPT | |
| SCHEMBL6417211 | 0.80 | CHRNA7 (0.63) | HSPA5KCNMA1CHRNA7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | claimed |
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | CEREP SA (FR) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124667-A1 | Oxamide inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | HSPA5 4261/4885KCNMA1 2149/4885POLB 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.